17:35 , Sep 28, 2018 |  BC Week In Review  |  Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Sept. 26, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400...
20:07 , Sep 26, 2018 |  BC Extra  |  Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Wednesday, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400 million...
17:47 , Jun 21, 2017 |  BC Extra  |  Financial News

Autoimmune play Syntimmune raises $50M

Autoimmune disease company Syntimmune Inc. (New York, N.Y.) raised $50 million in a series B round. Existing investor Apple Tree Partners invested $48 million to lead the round. Also participating were existing investors Partners Innovation...
19:06 , Jan 6, 2017 |  BioCentury  |  Emerging Company Profile

Gobbling globulins

Syntimmune Inc. is targeting a receptor that mediates the life span and activity of immunoglobulin G to control autoimmune disease more precisely and potentially more safely than broadly acting agents. The company aims to differentiate...
23:19 , Nov 1, 2016 |  BC Extra  |  Company News

Shire ends Sanfilippo A program, venture investing

In its 3Q16 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will terminate development of SHP610 after it missed the primary endpoint of a Phase IIb study to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo A...
07:00 , Sep 29, 2016 |  BC Innovations  |  Emerging Company Profile

Composite T cells

  While the specificity of γδ T cells gives them the potential to treat a broader array of cancers more safely than the αβ T cell therapies in the clinic, they may not persist long...
07:00 , Sep 15, 2016 |  BC Innovations  |  Product R&D

Enter GammaDelta

Lauren Martz, Senior Writer  Today's launch of Abingworth-backed GammaDelta Therapeutics Ltd. could signal the rise of γδ T cells as the newest class of cancer immunotherapies. The company is the second founded in as many...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

Medicxi's platform exception

Medicxi Ventures spurned its typical asset-centric model for the second time this month because the firm thought Gadeta B.V .'s T cell receptor platform was too good an opportunity to pass up. On March 29,...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Financial News

Gadeta completes venture financing

Gadeta B.V. , Utrecht, the Netherlands   Business: Cancer   Date completed: 2016-03-29   Type: Venture financing   Raised: EUR7 million ($7.8 million)   Investors: Baxalta Ventures; Medicxi Ventures; Utrecht University Holding; company founders; company...
01:31 , Mar 30, 2016 |  BC Extra  |  Financial News

Gadeta raises EUR 7M for T cell therapies

Gadeta B.V. (Utrecht, the Netherlands) raised EUR 7 million ($7.8 million) in a series A round led by Baxalta Ventures and Medicxi Ventures. Gadeta's founders, management and Utrecht Holdings also participated. Gadeta is developing optimized...